Postes actifs de Ulrik Mouritzen
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Breye Therapeutics ApS
 Breye Therapeutics ApS Pharmaceuticals: MajorHealth Technology Breye Therapeutics ApS is a biopharmaceutical company based in Copenhagen, Denmark. The Danish company develops novel, oral ophthalmology drugs to address the needs of millions of patients suffering from deteriorating vision due to diabetic retinopathy (DR) or age-related macular degeneration (AMD). Breye Therapeutics' lead program with Danegaptide has a clinically de-risked safety profile and potential for a short and well-accepted clinical regulatory pathway. The company aims to provide less burdensome and more effective treatments for DR and AMD patients, which are currently treated with unpopular intravitreal injections directly into the eye. The company was founded in 2019, and the CEO is Ulrik Mouritzen. | Directeur/Membre du Conseil | - | - |
| Directeur Général | - | - |
Historique de carrière de Ulrik Mouritzen
Statistiques
Internationale
| Danemark | 2 |
Opérationnelle
| Director/Board Member | 1 |
| Chief Executive Officer | 1 |
Sectorielle
| Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Breye Therapeutics ApS
Breye Therapeutics ApS Pharmaceuticals: MajorHealth Technology Breye Therapeutics ApS is a biopharmaceutical company based in Copenhagen, Denmark. The Danish company develops novel, oral ophthalmology drugs to address the needs of millions of patients suffering from deteriorating vision due to diabetic retinopathy (DR) or age-related macular degeneration (AMD). Breye Therapeutics' lead program with Danegaptide has a clinically de-risked safety profile and potential for a short and well-accepted clinical regulatory pathway. The company aims to provide less burdensome and more effective treatments for DR and AMD patients, which are currently treated with unpopular intravitreal injections directly into the eye. The company was founded in 2019, and the CEO is Ulrik Mouritzen. | Health Technology |
- Bourse
- Insiders
- Ulrik Mouritzen
- Expérience
